Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of Digitalization in Chronic Disease Management
4.2.2 Increasing Burden of Chronic Diseases
4.3 Market Restraints
4.3.1 High Cost of Instruments
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - in USD Million)
5.1 By Product
5.1.1 Hardware
5.1.2 Software
5.1.3 Services
5.2 By Diagnosis Type
5.2.1 Cardiology
5.2.2 Oncology
5.2.3 Neurology
5.2.4 Radiology
5.2.5 Pathology
5.2.6 Others
5.3 By End User
5.3.1 Hospitals and Clinics
5.3.2 Clinical Laboratories
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche Ltd
6.1.2 GE Healthcare
6.1.3 Siemens Healthcare GmbH
6.1.4 ThermoFisher Scientific Inc.
6.1.5 Laboratory Corporation of America Holdings
6.1.6 Digital Diagnostics Inc.
6.1.7 Cerora
6.1.8 Riverain Technologies
6.1.9 Midmark Corporation
6.1.10 Nanox Imaging Ltd.
6.1.11 Novasignal Corporation
6.1.12 Vuno Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS